GlassScriptPhysician profile
Abby K Baldwin
NPI 1740629625
$1,710.83
in general payments reported to CMS, 2019-2025
23 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $244 · 2021: $387 · 2022: $72.82 · 2023: $146 · 2024: $213 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.36 | 2021-2025 | Ubrelvy, Vraylar |
| Astellas Pharma US INC | $191.39 | 2020-2021 | |
| Glaxosmithkline, LLC. | $180.80 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $119.88 | 2019-2025 | |
| Novo Nordisk INC | $72.22 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $61.13 | 2021-2025 | Evenity |
| Merck Sharp & Dohme LLC | $45.07 | 2019-2023 | Dificid |
| Boston Scientific Corporation | $36.04 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $35.43 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $32.05 | 2021 | |
| Allergan, INC. | $31.94 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $29.81 | 2019 | |
| Dexcom, INC. | $20.07 | 2022 | |
| Corium, LLC | $19.81 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.66 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Exact Sciences Corporation | $14.73 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.37 | 2019 | |
| Axonics, INC. | $13.69 | 2023 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2023 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.08 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.07 | 2019 | |
| Currax Pharmaceuticals LLC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.